78 research outputs found
Concentration phase diagram of Ba(x)Sr(1-x)TiO3 solid solutions
Method of derivation of phenomenological thermodynamic potential of solid
solutions is proposed in which the interaction of the order parameters of
constituents is introduced through the account of elastic strain due to misfit
of the lattice parameters of the end-members. The validity of the method is
demonstrated for Ba(x)Sr(1-x)TiO3 system being a typical example of
ferroelectric solid solution. Its phase diagram is determined using
experimental data for the coefficients in the phenomenological potentials of
SrTiO3 and BaTiO3. In the phase diagram of the Ba(x)Sr(1-x)TiO3 system for
small Ba concentration, there are a tricritical point and two multiphase points
one of which is associated with up to 6 possible phases.Comment: 8 pages, 3 figure
Spin exchange between charged paramagnetic particles in dilute solutions
Β© Springer-Verlag Wien 2014. Kinetic equations for the spin density matrix which take into account binary collisions and a method of calculating the spin exchange effective radius have been generalized to the case of dilute solutions of charged paramagnetic particles. The effective radius of the spin exchange and rate constant of the bimolecular spin exchange between charged paramagnetic particles in solutions have been calculated numerically. Calculations have been performed under the assumption that the exchange interaction is isotropic and decays exponentially with the increase in the distance between radicals, and the solution has a given dielectric permittivity and Debye screening radius. Dependences of the spin exchange rate constant on the mutual diffusion coefficient, exchange and electrostatic interactions parameters have been found numerically. The theory has been applied to experimental results taken from the literature. The rate constant of the spin exchange between radicals of like charge found from the experiment and calculated within the developed theory are in good qualitative agreement
Solid-state 31P and 109Ag CP/MAS NMR as a powerful tool for studying of silver(I) complexes with N-thiophosphorylated thiourea and thioamide ligands
A family of three- and four-coordinated silver(I) complexes of formulas [Ag(PPh3)2L], [Ag(PPh3)L], and [AgL]n with N-thiophosphorylated thiourea and thioamide ligands of general formula RC(S)NHP(S)(OPri)2 [R = Ph, PhNH, iPrNH, tBuNH, NH2] have been studied by solid-state 109Ag and 31P CPMAS NMR spectroscopy. 109Ag NMR spectra have provided valuable structural information about Ag coordination, which is in good accordance with the available crystal structure data. The data presented in this work represent a significant addition to the available 109Ag chemical shifts and chemical shifts anisotropies. The silver chemical shift ranges for different P,S-environments and coordination state were discussed in detail. The 1J(31Pβ107/109Ag) and 2J(31Pβ31P) values were determined and analyzed. Β© 2022 John Wiley & Sons Ltd.Kazan Federal University: Priority-2030Financial support from the IR-RMN-THC Fr3050 CNRS for conducting the research is gratefully acknowledged. This paper has been supported by the Kazan Federal University Strategic Academic Leadership Program (Priority-2030).Financial support from the IR-RMN-THC Fr3050 CNRS for conducting the research is gratefully acknowledged. This paper has been supported by the Kazan Federal University Strategic Academic Leadership Program (Priority-2030)
Π£ΡΠΎΠ²Π΅Π½Ρ ΠΈ ΡΡΡΡΠΊΡΡΡΠ° ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ ΠΎΡ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈ ΠΊΡΠΎΠ²Π΅ΡΠ²ΠΎΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ Π² ΡΠ΅Π³ΠΈΠΎΠ½Π°Ρ Π Π΅ΡΠΏΡΠ±Π»ΠΈΠΊΠΈ ΠΠ°ΡΠΊΠΎΡΡΠΎΡΡΠ°Π½ (2006β2015 Π³Π³.)
Introduction. An urgent issue facing contemporary medicine is the problem of cancer. According to official Russian Federation statistical data, of the 2,132,050 deaths recorded in 2015, 286,900 of them resulted from cancer. In this connection, an analysis of mortality due to malignant neoplasms of lymphatic and hematopoietic tissues is a relevant activity.Materials and methods. We analysed data showing the dynamic rate and structure of mortality from malignant neoplasms of lymphatic and haematopoietic tissues in the Republic of Bashkortostan both of the population as a whole and persons of working age. Data covering the period 2006β2015 was derived from the Federal State Statistics Service for the Republic of Bashkortostan.Results and discussion. As a result of the research, an increase in the overall intensive mortality rates from malignant neoplasms of lymphatic and haematopoietic tissues was noted along with an absence of significant differences between the indicators in the Republic of Bashkortostan and those for the Russian Federation as a whole. Our work has shown that malignant neoplasms of haematopoietic and lymphoid tissues are the leading medical and social problem of contemporary oncology.Conclusion. This work was carried out in order to identify the most common clinical cases of malignant tumours of haematopoietic and lymphoid tissue, as well as to predict the incidence and further planning of specialised haematological care to the population.Β ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠ° ΡΠ΅Π³ΠΎΠ΄Π½ΡΡΠ½ΠΈΠΉ Π΄Π΅Π½Ρ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΠΌ Π²ΠΎΠΏΡΠΎΡΠΎΠΌ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Ρ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ. ΠΠΎ ΠΎΡΠΈΡΠΈΠ°Π»ΡΠ½ΡΠΌ Π΄Π°Π½Π½ΡΠΌ, Π² Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ Π·Π° 2015 Π³ΠΎΠ΄ ΡΠΌΠ΅ΡΠ»ΠΎ Π±ΠΎΠ»Π΅Π΅ 2 132 050 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ, ΠΈΠ· Π½ΠΈΡ
Ρ Π΄ΠΈΠ°Π³Π½ΠΎΠ·ΠΎΠΌ Β«ΡΠ°ΠΊΒ» ΡΠΌΠ΅ΡΠ»ΠΎ 286 900 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ. ΠΠ°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΡ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡΠΌΠΈ Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈ ΠΊΡΠΎΠ²Π΅ΡΠ²ΠΎΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ Π½Π°Π½ΠΎΡΠΈΡ ΡΡΠ΅ΡΠ± ΠΎΠ±ΡΠ΅ΡΡΠ²Ρ ΠΈ Π·Π°Π½ΠΈΠΌΠ°Π΅Ρ Π²Π΅Π΄ΡΡΠΈΠ΅ ΠΏΠΎΠ·ΠΈΡΠΈΠΈ Π² ΠΌΠΈΡΠ΅. Π ΡΠ²ΡΠ·ΠΈ ΡΒ ΡΡΠΈΠΌ Π±ΡΠ΄Π΅Ρ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΠΌ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ Π°Π½Π°Π»ΠΈΠ·Π° ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ ΠΎΡ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈ ΠΊΡΠΎΠ²Π΅ΡΠ²ΠΎΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ»Ρ ΡΡΠΎΠ³ΠΎ Π½Π°ΠΌΠΈ Π±ΡΠ»ΠΈ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ Π΄Π°Π½Π½ΡΠ΅, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΠΈΠ΅ ΡΡΠΎΠ²Π΅Π½Ρ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ ΠΈΒ ΡΡΡΡΠΊΡΡΡΡ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ ΠΎΡ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈ ΠΊΡΠΎΠ²Π΅ΡΠ²ΠΎΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ Π² ΡΠ΅Π³ΠΈΠΎΠ½Π°Ρ
Π Π΅ΡΠΏΡΠ±Π»ΠΈΠΊΠΈ ΠΠ°ΡΠΊΠΎΡΡΠΎΡΡΠ°Π½ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ Π² ΡΠ΅Π»ΠΎΠΌ ΠΈ Π»ΠΈΡ ΡΡΡΠ΄ΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° ΠΏΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π°ΠΌ Π’Π΅ΡΡΠΈΡΠΎΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΎΡΠ³Π°Π½Π° Π€Π΅Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ»ΡΠΆΠ±Ρ Π³ΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠΈ ΠΏΠΎ Π Π Π·Π° 2006β2015 Π³Π³.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. Π ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π½Π°ΠΌΠΈ Π±ΡΠ»ΠΎ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΠΎΠ±ΡΠΈΡ
ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ ΠΎΡ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈ ΠΊΡΠΎΠ²Π΅ΡΠ²ΠΎΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ ΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΡΠ°Π·Π»ΠΈΡΠΈΠΉ ΠΌΠ΅ΠΆΠ΄Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ Π² ΡΠ΅Π»ΠΎΠΌ ΠΏΠΎ Π Π΅ΡΠΏΡΠ±Π»ΠΈΠΊΠ΅ ΠΠ°ΡΠΊΠΎΡΡΠΎΡΡΠ°Π½ Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ ΠΏΠΎ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ. ΠΡΠΎΠ΄Π΅Π»Π°Π½Π½Π°Ρ Π½Π°ΠΌΠΈ ΡΠ°Π±ΠΎΡΠ° ΠΏΠΎΠΊΠ°Π·Π°Π»Π°, ΡΡΠΎ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΊΡΠΎΠ²Π΅ΡΠ²ΠΎΡΠ½ΠΎΠΉ ΠΈΒ Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ ΡΠ²Π»ΡΡΡΡΡ Π²Π΅Π΄ΡΡΠ΅ΠΉ ΠΌΠ΅Π΄ΠΈΠΊΠΎ-ΡΠΎΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠΎΠΉ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ°Π½Π½Π°Ρ ΡΠ°Π±ΠΎΡΠ° ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° Ρ ΡΠ΅Π»ΡΡ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΠΎ Π²ΡΡΡΠ΅ΡΠ°ΡΡΠΈΡ
ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ»ΡΡΠ°Π΅Π² Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ ΠΊΡΠΎΠ²Π΅ΡΠ²ΠΎΡΠ½ΠΎΠΉ ΠΈ Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΈ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅Π³ΠΎ ΠΏΠ»Π°Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Π³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠΎΡΠΈ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ.
Π Π°ΠΊ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ·ΠΎΠΌ
Introduction. Chronic lymphocytic leukaemia (CLL) is a malignant clonal lymphoproliferative disorder characterised by the accumulation of atypical mature CD5/CD19/CD23-positive B lymphocytes, predominantly in blood, bone marrow, lymph glands, liver and spleen. Chemotherapy protocols with the inclusion of nucleotide analogues, alkylating drugs and monoclonal antibodies are currently the standard of treatment. FCR (fludarabine, cyclophosphamide, rituximab) is one of the most effective protocols. CLL may lead to various immunologic disorders resulting in an increased risk of a malignant neoplasm. This paper aims to present a demonstration of a case of the combination of chronic lymphocytic leukaemia and stomach cancer, and an attempt to establishΒ β based on literature dataΒ β a link between the diagnosed stomach adenocarcinoma and the main disease.Materials and methods. Authors have analysed the case history, laboratory and instrumental data and the treatment of aΒ patient with chronic lymphocytic leukaemia and stomach adenocarcinoma.Results and discussion. The patient E., 63 yo, was diagnosed with chronic lymphocytic leukaemia in 2016. The patient was started on FCR chemotherapy protocol (Fludarabine, 70 mg days 2-4 of CT, Endoxan 500 mg days 2-4 of the cycle, Rituximab 700 mg day 1 od CT) in June 2018. When the patient came to the BSMU hospital for a chemotherapy cycle in August 2018, gastric endoscopy was performed; tissue pathology examination resulted in the diagnosis of stomach adenocarcinoma. A concilium of surgeons, oncologists and haematologists made a decision to perform a gastrectomy with the oesophageal resection and Roux anastomosis.Conclusion. Having used a clinical case as an example and reviewed available literature, the authors have demonstrated that either CLL or the immunosuppressed status served as the causal factors for the development of the adenocarcinoma. The development of stomach adenocarcinoma in patients with chronic lymphocytic leukaemia makes the course and outcome of the main disease much more severe. A decision regarding the management strategy for such patients has to make individually every time, taking into account the severity of the oncological disease; this impacts on the choice of the treatment protocol. All the cases of spontaneous remissions in patients with lymphocytic leukaemia must be screened extensively in order to facilitate early diagnosis of malignant neoplasms.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π₯ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ Π»ΠΈΠΌΡΠΎΡΠΈΡΠ°ΡΠ½ΡΠΉ Π»Π΅ΠΉΠΊΠΎΠ· (Π₯ΠΠ)Β β Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½ΠΎΠ΅ Π»ΠΈΠΌΡΠΎΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠ²Π½ΠΎΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅, ΠΊΠΎΡΠΎΡΠΎΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΠ΅ΡΡΡ Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΠ΅ΠΌ Π°ΡΠΈΠΏΠΈΡΠ½ΡΡ
Π·ΡΠ΅Π»ΡΡ
CD5/CD19/CD23-ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΡ
Π-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ Π² ΠΊΡΠΎΠ²ΠΈ, ΠΊΠΎΡΡΠ½ΠΎΠΌ ΠΌΠΎΠ·Π³Π΅, Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»Π°Ρ
, ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΈ ΡΠ΅Π»Π΅Π·Π΅Π½ΠΊΠ΅. Π‘ΡΠ°Π½Π΄Π°ΡΡΠΎΠΌ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠ²Π»ΡΡΡΡΡ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅ΠΆΠΈΠΌΡ Ρ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ΠΌ Π½ΡΠΊΠ»Π΅ΠΎΡΠΈΠ΄Π½ΡΡ
Π°Π½Π°Π»ΠΎΠ³ΠΎΠ², Π°Π»ΠΊΠΈΠ»ΠΈΡΡΡΡΠΈΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΠΈ ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½ΡΡ
Π°Π½ΡΠΈΡΠ΅Π». ΠΠ΄ΠΈΠ½ ΠΈΠ· Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΡΠ΅ΠΆΠΈΠΌΠΎΠ²Β β FCR (Π°Π½Π³Π». fludarabine, cyclophosphamide, rituximab). Π₯ΠΠ ΠΌΠΎΠΆΠ΅Ρ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡΡ ΠΊ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌ, ΠΊΠΎΡΠΎΡΡΠ΅, Π²Β ΡΠ²ΠΎΡ ΠΎΡΠ΅ΡΠ΅Π΄Ρ, ΠΏΠΎΠ²ΡΡΠ°ΡΡ ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ. Π¦Π΅Π»ΡΡ Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΡ ΡΠ²Π»ΡΠ΅ΡΡΡ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠ°ΡΠΈΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ»ΡΡΠ°Ρ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΡ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ·Π° Ρ ΡΠ°ΠΊΠΎΠΌ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° ΠΈ ΠΏΠΎΠΏΡΡΠΊΠ° Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ Π΄Π°Π½Π½ΡΡ
Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ ΡΠ²ΡΠ·Ρ Π²ΡΡΠ²Π»Π΅Π½Π½ΠΎΠΉ Π°Π΄Π΅Π½ΠΎΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° Ρ ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ΠΌ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠ»Π° ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π° ΠΈΡΡΠΎΡΠΈΡ Π±ΠΎΠ»Π΅Π·Π½ΠΈ, Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎ-ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΠ΅ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ·ΠΎΠΌ ΠΈ Π°Π΄Π΅Π½ΠΎΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠΎΠΉ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. Π£ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Π., 63 Π»Π΅Ρ, Π² 2016 Π³ΠΎΠ΄Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°Π½ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ·, Π½Π°ΡΠ°Ρ ΠΏΡΠΈΠ΅ΠΌ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΠΎ ΡΡ
Π΅ΠΌΠ΅ FCR (Π€Π»ΡΠ΄Π°ΡΠ°Π±ΠΈΠ½ 70 ΠΌΠ³ 2β4 Π΄Π΅Π½Ρ Π₯Π’, ΠΠ½Π΄ΠΎΠΊΡΠ°Π½ 500 ΠΌΠ³ 2β4-ΠΉ Π΄Π΅Π½Ρ ΡΠΈΠΊΠ»Π°, Π ΠΈΡΡΠΊΡΠΈΠΌΠ°Π± 700 ΠΌΠ³ 1βΠΉ Π΄Π΅Π½Ρ Π₯Π’) Ρ ΠΈΡΠ½Ρ 2018 Π³. Π Π°Π²Π³ΡΡΡΠ΅ 2018 Π³ΠΎΠ΄Π° ΠΏΡΠΈ ΠΏΠΎΡΡΡΠΏΠ»Π΅Π½ΠΈΠΈ Π² ΠΠ»ΠΈΠ½ΠΈΠΊΡ ΠΠΠΠ£ Π½Π° ΠΎΡΠ΅ΡΠ΅Π΄Π½ΠΎΠΉ ΠΊΡΡΡ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±ΡΠ»Π° ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΡΠΈΠ±ΡΠΎΠ³Π°ΡΡΡΠΎΡΠΊΠΎΠΏΠΈΡ, Π³Π΄Π΅ Π² ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°Π»ΠΈ Π°Π΄Π΅Π½ΠΎΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°. ΠΠΎΠ½ΡΠΈΠ»ΠΈΡΠΌΠΎΠΌ Π² ΡΠΎΡΡΠ°Π²Π΅ Ρ
ΠΈΡΡΡΠ³ΠΎΠ², ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΎΠ² ΠΈ Π³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΎΠ² Π±ΡΠ»ΠΎ ΠΏΡΠΈΠ½ΡΡΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΎ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠΈ Π³Π°ΡΡΡΡΠΊΡΠΎΠΌΠΈΠΈ Ρ ΡΠ΅Π·Π΅ΠΊΡΠΈΠ΅ΠΉ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π° Ρ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π°Π½Π°ΡΡΠΎΠΌΠΎΠ·Π° ΠΏΠΎ Π Ρ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ° ΠΏΡΠΈΠΌΠ΅ΡΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ»ΡΡΠ°Ρ ΠΈ ΠΎΠ±Π·ΠΎΡΠ° Π΄ΠΎΡΡΡΠΏΠ½ΠΎΠΉ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ, ΡΡΠΎ ΠΏΡΠΈΡΠΈΠ½Π½ΡΠΌΠΈ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π°Π΄Π΅Π½ΠΎΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° ΠΌΠΎΠ³Π»ΠΈ ΠΏΠΎΡΠ»ΡΠΆΠΈΡΡ Π»ΠΈΠ±ΠΎ Π₯ΠΠ, Π»ΠΈΠ±ΠΎ ΠΈΠΌΠΌΡΠ½ΠΎΡΡΠΏΡΠ΅ΡΡΠΈΠ²Π½ΠΎΠ΅ ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅. ΠΠ°Π»ΠΈΡΠΈΠ΅ Π°Π΄Π΅Π½ΠΎΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ·ΠΎΠΌ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΎΡΠ»ΠΎΠΆΠ½ΡΠ΅Ρ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΈ ΠΈΡΡ
ΠΎΠ΄ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. Π Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠ°ΠΊΡΠΈΠΊΠΈ Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΡΠΈΠ½ΠΈΠΌΠ°Π΅ΡΡΡ ΠΊΠ°ΠΆΠ΄ΡΠΉ ΡΠ°Π· ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΠΎ Ρ ΡΡΠ΅ΡΠΎΠΌ ΡΡΠΆΠ΅ΡΡΠΈ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈ Π²Π»ΠΈΡΠ΅Ρ Π½Π° Π²ΡΠ±ΠΎΡ ΡΡ
Π΅ΠΌΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠΌΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΡΠΈ ΡΡΠΎΠΌ Π²ΡΠ΅ ΡΠ»ΡΡΠ°ΠΈ ΡΠΏΠΎΠ½ΡΠ°Π½Π½ΡΡ
ΡΠ΅ΠΌΠΈΡΡΠΈΠΉ ΠΏΡΠΈ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ·Π΅ Π΄ΠΎΠ»ΠΆΠ½Ρ ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°ΡΡΡΡ ΡΠ°ΡΡΠΈΡΠ΅Π½Π½ΡΠΌ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³ΠΎΠΌ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΡΠ°Π½Π½Π΅ΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ
ΠΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΠΈΡΡΠ΅ΠΌΡ Π³Π΅ΠΌΠΎΡΡΠ°Π·Π° Ρ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ Ρ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½Π½ΡΠΌ Π°ΠΊΡΡΠ΅ΡΡΠΊΠΈΠΌ Π°Π½Π°ΠΌΠ½Π΅Π·ΠΎΠΌ
Introduction. A number of researchers point at a direct connection between mutations of genes affecting the haemostasisΒ system and risks of venous thromboembolism and / or infertility. Quite often,Β a thrombophilia diagnosis is a result ofΒ overdiagnosis, which may lead to ungrounded and evenΒ dangerous medical prescriptions. In this context, the key goalΒ of this work was to analyse theΒ homeostasis system in women with recurrent pregnancy loss and establishes the causesΒ of this phenomenon.Materials and methods. Over the course of this work, we analysed 79 women in various stages of pregnancy who wereΒ receiving treatment in the Pregnancy Pathology Department of the BSMU Clinic. We analysed their medical histories,Β Body Mass Indexes (BMI), polymorphisms of haemostasis system genes and thrombosis risk factors.Results and discussion. BMI analysis found normal body mass in 39 patients (49.4 %) and excessive body mass in 40 patientsΒ (50.6 %). F2 and F5 gene polymorphisms were almost entirely absent. ITGA2Β and ITGB3 gene mutations wereΒ found in the patients analysed in 48.1 % and 17.7 % of the cases,Β respectively. PAI-1 gene mutations were found in 84.8 %Β of cases. MTR and MTRR gene polymorphismsΒ were detected in 35.4 % and 81.0 % of the patients, respectively. MTHFRΒ mutations were found in more than 40 % of the patients.Conclusion. Obesity and hereditary thrombophilia are primary factors in venous thromboembolism. Body weight lossΒ and antithrombotic therapy reduce risk obstetric complications, improving prognosis and pregnancy outcomes.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠΎ Π΄Π°Π½Π½ΡΠΌ ΡΡΠ΄Π° ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»Π΅ΠΉ, ΠΈΠΌΠ΅Π΅ΡΡΡ ΠΏΡΡΠΌΠ°Ρ ΡΠ²ΡΠ·Ρ ΠΌΠ΅ΠΆΠ΄Ρ ΠΌΡΡΠ°ΡΠΈΡΠΌΠΈ Π³Π΅Π½ΠΎΠ² ΡΠΈΡΡΠ΅ΠΌΡ Π³Π΅ΠΌΠΎΡΡΠ°Π·Π°ΠΈ ΡΠΈΡΠΊΠ°ΠΌΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π²Π΅Π½ΠΎΠ·Π½ΠΎΠΉ ΡΡΠΎΠΌΠ±ΠΎΡΠΌΠ±ΠΎΠ»ΠΈΠΈ ΠΈ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΡ. ΠΠ΅ΡΠ΅Π΄ΠΊΠΎ Π΄ΠΈΠ°Π³Π½ΠΎΠ· ΡΡΠΎΠΌΠ±ΠΎΡΠΈΠ»ΠΈΡ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ»Π΅Π΄ΡΡΠ²ΠΈΠ΅ΠΌΒ Π³ΠΈΠΏΠ΅ΡΠ΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ, ΠΏΡΠΈΠ²ΠΎΠ΄ΡΡΠ΅ΠΉ ΠΊ Π½Π΅ΠΎΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½Π½ΠΎΠΌΡ ΠΈ Π΄Π°ΠΆΠ΅ ΠΎΠΏΠ°ΡΠ½ΠΎΠΌΡ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ². ΠΒ ΡΡΠΎΠΉ ΡΠ²ΡΠ·ΠΈ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ ΡΠ΅Π»ΡΡ Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΡ ΡΠ²Π»ΡΠ΅ΡΡΡ Π°Π½Π°Π»ΠΈΠ· ΡΠΈΡΡΠ΅ΠΌΡ Π³Π΅ΠΌΠΎΡΡΠ°Π·Π° Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ ΠΏΡΠΈΠ²ΡΡΠ½ΡΠΌΒ Π½Π΅Π²ΡΠ½Π°ΡΠΈΠ²Π°Π½ΠΈΠ΅ΠΌ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ ΠΈ Π²ΡΡΠ²Π»Π΅Π½ΠΈΠ΅ΠΌ ΠΏΡΠΈΡΠΈΠ½ Π½Π΅Π²ΡΠ½Π°ΡΠΈΠ²Π°Π½ΠΈΡ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· 79 ΠΈΡΡΠΎΡΠΈΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΆΠ΅Π½ΡΠΈΠ½ Π½Π° ΡΠ°Π·Π½ΡΡ
ΡΡΠΎΠΊΠ°Ρ
Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ, ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΡΠ΅ΡΠ°ΠΏΠΈΡ Π² ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΠΈ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ ΠΠ»ΠΈΠ½ΠΈΠΊΠΈ ΠΠΠΠ£. ΠΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈΡΡ Π°Π½Π°ΠΌΠ½Π΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΒ Π°Π½ΡΡΠΎΠΏΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π΄Π°Π½Π½ΡΠ΅, ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π½Π° ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΡ Π³Π΅Π½ΠΎΠ² ΡΠΈΡΡΠ΅ΠΌΡ Π³Π΅ΠΌΠΎΡΡΠ°Π·Π° ΠΆΠ΅Π½ΡΠΈΠ½ ΠΈΒ ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ².Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. ΠΡΠΈ Π°Π½Π°Π»ΠΈΠ·Π΅ ΠΈΠ½Π΄Π΅ΠΊΡΠ° ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π° β Π½ΠΎΡΠΌΠ° ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π° Ρ 39 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (49,4 %) ΠΈ ΠΏΡΠ΅Π²ΡΡΠ΅Π½ΠΈΠ΅ ΠΈΠ½Π΄Π΅ΠΊΡΠ° ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π° Ρ 40 (50,6 %). ΠΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΡ Π³Π΅Π½ΠΎΠ² F2 ΠΈ F5 ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅ Π±ΡΠ»ΠΈ Π²ΡΡΠ²Π»Π΅Π½Ρ.Β ΠΡΡΠ°ΡΠΈΠΈΒ Π³Π΅Π½ΠΎΠ² ITGA2 ΠΈ ITGB3 ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ Ρ ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π² 48,1 ΠΈ 17,7 % ΡΠ»ΡΡΠ°Π΅Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ.Β ΠΡΡΠ°ΡΠΈΡΒ Π³Π΅Π½Π° PAI-1 Π²ΡΡΠ²Π»Π΅Π½Π° Π² 84,8 % ΡΠ»ΡΡΠ°Π΅Π². ΠΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΡ Π³Π΅Π½ΠΎΠ² MTR ΠΈ MTRR Π²ΡΡΠ²Π»Π΅Π½Ρ Ρ 35,4 ΠΈ 81,0 %Β ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²Β ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΡΡΠ°ΡΠΈΠΈ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠΎΠ² Π³Π΅Π½ΠΎΠ² MTHFR Π²ΡΡΠ²Π»Π΅Π½Ρ Π±ΠΎΠ»Π΅Π΅ ΡΠ΅ΠΌ Ρ 40 % ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ².ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΆΠΈΡΠ΅Π½ΠΈΠ΅ ΠΈ Π½Π°ΡΠ»Π΅Π΄ΡΡΠ²Π΅Π½Π½Π°Ρ ΡΡΠΎΠΌΠ±ΠΎΡΠΈΠ»ΠΈΡ ΡΠ²Π»ΡΡΡΡΡ ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌΠΈ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΡΠΎΠΌΠ±ΠΎΡΠΌΠ±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ. ΠΡΠ΅Π³ΡΠ°Π²ΠΈΠ΄Π°ΡΠ½ΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π° ΠΈ ΡΠ°Π½Π½ΡΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠ΅ΡΠΊΠ°ΡΒ ΡΠ΅ΡΠ°ΠΏΠΈΡΒ ΡΠΌΠ΅Π½ΡΡΠ°ΡΡ ΡΠΈΡΠΊ Π°ΠΊΡΡΠ΅ΡΡΠΊΠΈΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΠΈ ΡΠ»ΡΡΡΠ°ΡΡ ΠΏΡΠΎΠ³Π½ΠΎΠ· ΠΈ ΠΈΡΡ
ΠΎΠ΄Ρ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ
Corporoplasty in Peyronieβs Disease: a Literature Review
Corporoplasty is urological correction surgery for penile deviation that causes copulatory dysfunction or aesthetic discomfort. Penile deviation can be congenital or acquired (Peyronieβs disease, penile fracture). Congenital penile deviation is relatively rare and manifests in the curvature of erect penis ventrally and/or laterally, in most cases. According to many studies, patients with curvatures of 30Β° or more eventually seek surgical treatment. Congenital curvature may be mistaken for Peyronieβs disease for similar manifestations that, however, differ in aetiology and pathophysiology. Excisional, incisional corporoplasty or plication are commonly engaged to treat congenital curvatures, in various techniques and modifications. Augmentation transplantation (grafting) and penile prosthesis implantation with variant deviation treatment options are the usual practice in Peyronieβs disease. Unequivocal judgment of pros and cons in any particular technique is nevertheless implausible to make. This article aims to review current trends, protocols and their relative advantages in corporoplasty
Features of laboratory indices in workers of chemical production with occupational skin diseases
Changes of haematological and biochemical indices depending on the nosological entities of occupational diseases and the gender were analyzed in workers of chemical complex. Changes of these indices depending on the gender identity were revealed in workers with skin hyperkeratinization at the conduction of medical examination. Eosinophilia, lymphocytosis and leukopenia were revelaed in men with hyperkeratinization, increase of hemoglobin quantity and leukopenia were revealed in women with hyperkeratinization. There were no differences depending on the gender in patients with skin cancer
- β¦